270 related articles for article (PubMed ID: 29487385)
1. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
Bae J; Hideshima T; Tai YT; Song Y; Richardson P; Raje N; Munshi NC; Anderson KC
Leukemia; 2018 Sep; 32(9):1932-1947. PubMed ID: 29487385
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.
Bae J; Hideshima T; Zhang GL; Zhou J; Keskin DB; Munshi NC; Anderson KC
Leukemia; 2018 Mar; 32(3):752-764. PubMed ID: 29089645
[TBL] [Abstract][Full Text] [Related]
3. Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
Ray A; Song Y; Du T; Chauhan D; Anderson KC
Oncogene; 2020 Mar; 39(13):2786-2796. PubMed ID: 32024967
[TBL] [Abstract][Full Text] [Related]
4. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
Bae J; Smith R; Daley J; Mimura N; Tai YT; Anderson KC; Munshi NC
Clin Cancer Res; 2012 Sep; 18(17):4850-60. PubMed ID: 22753586
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
[TBL] [Abstract][Full Text] [Related]
6. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.
Bae J; Prabhala R; Voskertchian A; Brown A; Maguire C; Richardson P; Dranoff G; Anderson KC; Munshi NC
Leukemia; 2015 Jan; 29(1):218-29. PubMed ID: 24935722
[TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
8. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.
Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B
J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156
[TBL] [Abstract][Full Text] [Related]
9. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
10. CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
Altvater B; Pscherer S; Landmeier S; Niggemeier V; Juergens H; Vormoor J; Rossig C
Clin Exp Immunol; 2006 Jun; 144(3):447-57. PubMed ID: 16734614
[TBL] [Abstract][Full Text] [Related]
11. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
Bae J; Tai YT; Anderson KC; Munshi NC
Br J Haematol; 2011 Nov; 155(3):349-61. PubMed ID: 21902685
[TBL] [Abstract][Full Text] [Related]
12. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.
Bae J; Carrasco R; Lee AH; Prabhala R; Tai YT; Anderson KC; Munshi NC
Leukemia; 2011 Oct; 25(10):1610-9. PubMed ID: 21660045
[TBL] [Abstract][Full Text] [Related]
14. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R
Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625
[TBL] [Abstract][Full Text] [Related]
15. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
García-Guerrero E; Götz R; Doose S; Sauer M; Rodríguez-Gil A; Nerreter T; Kortüm KM; Pérez-Simón JA; Einsele H; Hudecek M; Danhof S
Leukemia; 2021 Jan; 35(1):201-214. PubMed ID: 32350373
[TBL] [Abstract][Full Text] [Related]
17. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M
J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735
[TBL] [Abstract][Full Text] [Related]
18. Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control.
Nilofar Danishmalik S; Lee SH; Sin JI
Oncotarget; 2017 Apr; 8(16):26771-26788. PubMed ID: 28460461
[TBL] [Abstract][Full Text] [Related]
19. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.
Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; Hooijberg E; Kramer D; Reurs AW; van den Eertwegh AJ; von Blomberg BM; Scheper RJ; Bontkes HJ
J Immunol; 2008 Aug; 181(4):2446-54. PubMed ID: 18684935
[TBL] [Abstract][Full Text] [Related]
20. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
